about
Tumor Microenvironment Metabolism: A New Checkpoint for Anti-Tumor ImmunityAdvances in Cancer Immunotherapy in Solid TumorsBlimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia.Hurdles to the Development of Effective HBV Immunotherapies and HCV VaccinesMaking Better Chimeric Antigen Receptors for Adoptive T-cell TherapyFuture perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.Markers of T Cell Senescence in Humans.Interleukin-2 reverses CD8(+) T cell exhaustion in clinical malignant pleural effusion of lung cancer.Emerging Opportunities and Challenges in Cancer Immunotherapy.Evolving Immunotherapy Approaches for Renal Cell Carcinoma.Intraperitoneal immunotherapy: historical perspectives and modern therapy.LAG3 (CD223) as a cancer immunotherapy target.Role of Type I and II Interferons in Colorectal Cancer and Melanoma.The Potential and Challenges of Exploiting the Vast But Dynamic Neoepitope Landscape for Immunotherapy.Is Graves' disease a primary immunodeficiency? New immunological perspectives on an endocrine disease.IL-27 mediates HLA class I up-regulation, which can be inhibited by the IL-6 pathway, in HLA-deficient Small Cell Lung Cancer cells.Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review)Ablation of Transcription Factor IRF4 Promotes Transplant Acceptance by Driving Allogenic CD4+ T Cell Dysfunction.Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate.Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences.Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes?The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective.Interferon-γ converts human microvascular pericytes into negative regulators of alloimmunity through induction of indoleamine 2,3-dioxygenase 1.Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients.Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy.Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.Development of a vaccine based on bacteria-mimicking tumor cells coated with novel engineered toll-like receptor 2 ligands.Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma.Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology.PD-1+ TIM-3+ T cells in malignant ascites predict prognosis of gastrointestinal cancer
P2860
Q28077647-3BBAA71D-0BFC-437A-9133-45393AF4524CQ28080113-D92319E4-18E5-441C-AAAD-C7300AC1CDDFQ33814411-3D3E0DB1-0048-42B5-906A-70776FD3BEFFQ33840260-539B91D6-6BC8-4731-8207-652AFF56AFA0Q36830759-DEAFC934-1FFE-4B2D-9963-ECBFD2E86B38Q37417271-4353603E-4AFE-4FB6-AB38-5811CA1C9F63Q38644422-AACC5134-06A2-4F50-B9AC-DB8CD2A727A9Q38756417-66F9F8C3-B151-42EA-B302-F9342B26436EQ38809772-3ADEB7CA-F13F-4337-888F-1F7B445D98F7Q38913703-D3D4F58C-8047-4A18-B6EA-806808A2B0E3Q39005211-FB05DF6B-0C96-4781-82F9-9430449A08EFQ39160974-AB98D57E-D4EA-4914-ABC9-40B29976FDF3Q41123286-93D483D0-E462-45BB-9FF6-AB3618370DA0Q41673084-02595F5E-AA93-4821-B93A-BB30F2900537Q42225256-81694D5A-7EBC-4511-92C1-AA1AD6E9AEEEQ42375251-CA86AA0A-6B9C-4ADF-A463-601E44B4D078Q42378297-C8437D12-5136-415A-852E-F245D9EFF393Q46158379-A1D4C33C-F876-4848-803B-E0B3BF3B0E1AQ46721978-840A9051-AAFD-4E59-8714-1ACEC3D277D7Q47571555-7E7C4576-AD1A-4522-B464-D5387045BB9AQ48306002-B32F6D99-F5B9-4020-9732-33C9EDEFE7DFQ49196046-660D7C9D-5502-4EED-B250-483D48745E10Q50033731-5431E7C7-B94F-4F0C-9CC1-00E6B9DA3EEEQ50532036-8A1DC478-0545-4844-A689-931C174D22E8Q51201669-B75A5722-5A24-4A35-8B93-6774C76302C3Q52606149-C2443F2F-F193-4FA5-9C72-7A07D22DAA68Q53068034-9CB8CCEF-E346-434F-A1C2-87EE47E59B3AQ54943714-397921D5-21F8-4396-98F9-1B15870B6482Q55008075-158D071C-04FC-4ACA-AC83-9A263C1D2F67Q55386131-4950161F-9A5B-489B-8E41-6D7386203E55Q58763386-BBD74405-6C5B-4A22-BC39-2658C179E094
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Reversing T-cell Dysfunction and Exhaustion in Cancer.
@en
type
label
Reversing T-cell Dysfunction and Exhaustion in Cancer.
@en
prefLabel
Reversing T-cell Dysfunction and Exhaustion in Cancer.
@en
P2860
P1476
Reversing T-cell Dysfunction and Exhaustion in Cancer.
@en
P2093
Hassane M Zarour
P2860
P304
P356
10.1158/1078-0432.CCR-15-1849
P407
P577
2016-04-01T00:00:00Z